PD-L1 N-linked glycosylation was noted in breast cancer patient tumors, and following removal of N-linked glycosylation, PD-L1 levels correlated with response rates to anti-PD-L1 therapy [23,24]. This evidence concerns the gene CD274 and breast cancer.